ArticleJournal of comparative effectiveness research2022

Palbociclib versus abemaciclib in HR+/HER2- advanced breast cancer: an indirect comparison of patient-reported end points.

Ernest Law et al.PubMed ↗Publisher ↗

No numbers read from the abstract.